Development of 4-hexadecyl-4,7-diaza-1,10-decanedithiol (HDD) kit for the preparation of the liver cancer therapeutic agent Re-188-HDD/lipiodol

Banka, Vinay Kumar; Moon, Seol Ju; Jeong, Jae Min; Seelam, Sudhakara Reddy; Lee, Yun Sang; Kim, Young Joo; Lee, Dong Hoon; Chung, June Key

doi:10.1016/j.nucmedbio.2014.11.013

Cited by 10 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, the 188 Re-HDD complex was renamed 188 Re-HTDD, being more consistent with initial results with TDD, T standing for tetramethyl. A new HDD compound was then developed, without the four methyl groups [34] (Figure 2). This new compound showed a significantly higher extraction yield into Lipiodol with 90.2 ± 2.6 %.…”

Section: Introductionmentioning

confidence: 99%

Transarterial Radionuclide Therapy with 188Re-Labelled Lipiodol

Lepareur¹

2017

Int. J. Nucl. Medi. Res.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is usually detected late, in patients with advanced disease, who are thus not eligible for radical therapy. Despite this grim scenario, new treatment options for intermediate to advanced stages hold great promise, such as internal radionuclide therapy. Several techniques have been developed for radionuclide therapy of HCC. Among these, use of transarterial injection of a radiolabelled embolizing agent, such as microspheres or Lipiodol, has led to very encouraging results. Over the last few years, efforts to label Lipiodol with rhenium-188, an attractive beta-emitter, have led to a very active area of research. Lipiodol has been labelled either directly or by solubilisation of a lipophilic 188 Re-labelled complex. Preliminary clinical findings indicate the feasibility of using 188 Relabelled Lipiodol, which has shown good tolerance and good response rates in the treatment of unresectable HCC as well as in adjuvant or neo-adjuvant settings.

show abstract

Section: Introductionmentioning

confidence: 99%

Transarterial Radionuclide Therapy with 188Re-Labelled Lipiodol

Lepareur¹

2017

Int. J. Nucl. Medi. Res.

View full text Add to dashboard Cite

show abstract

“…The next generation compounds, such as 188 ReN-DEDC and 188 Re-SSS, demonstrated higher yields and higher in vivo stabilities (183, 199) (Figure 7). A newly developed HDD complex (201) is expected to solve the problems encountered with the previous HDD, but no clinical data are available yet.…”

Section: Re Particulatesmentioning

confidence: 99%

Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives

et al. 2019

View full text Add to dashboard Cite

Rhenium-188 ( 188 Re) is a high energy beta-emitting radioisotope with a short 16.9 h physical half-life, which has been shown to be a very attractive candidate for use in therapeutic nuclear medicine. The high beta emission has an average energy of 784 keV and a maximum energy of 2.12 MeV, sufficient to penetrate and destroy targeted abnormal tissues. In addition, the low-abundant gamma emission of 155 keV (15%) is efficient for imaging and for dosimetric calculations. These key characteristics identify 188 Re as an important therapeutic radioisotope for routine clinical use. Moreover, the highly reproducible on-demand availability of 188 Re from the 188 W/ 188 Re generator system is an important feature and permits installation in hospital-based or central radiopharmacies for cost-effective availability of no-carrier-added (NCA) 188 Re. Rhenium-188 and technetium-99 m exhibit similar chemical properties and represent a “theranostic pair.” Thus, preparation and targeting of 188 Re agents for therapy is similar to imaging agents prepared with 99m Tc, the most commonly used diagnostic radionuclide. Over the last three decades, radiopharmaceuticals based on 188 Re-labeled small molecules, including peptides, antibodies, Lipiodol and particulates have been reported. The successful application of these 188 Re-labeled therapeutic radiopharmaceuticals has been reported in multiple early phase clinical trials for the management of various primary tumors, bone metastasis, rheumatoid arthritis, and endocoronary interventions. This article reviews the use of 188 Re-radiopharmaceuticals which have been investigated in patients for cancer treatment, demonstrating that 188 Re represents a cost effective alternative for routine clinical use in comparison to more expensive and/or less readily available therapeutic radioisotopes.

show abstract

“…Bifunctional chelators designed to accommodate the structural preferences of the [ReO] 3+ offer a more reliable strategy. Use and further design [20] of tetradentate ligands containing a combination of amino/amido and thiolate donors [21] such as MAG3 [22] (Figure 3a) and cysteine-containing amino acid sequences [23,24] (Figure 2), developed in the 1990s, [11] have remained popular for attachment to lipids [25,26] and peptides, [22,[27][28][29][30][31][32] or simple complexes designed for rapid renal excretion in the context of radionuclide therapy during balloon angioplasty, [33,34] has continued. Re analogues were synthesised and shown to have identical structure and isomerism [6,7] (Figure 3b) and biodistribution (targeting medullary thyroid carcinoma and bone metastases in prostate, lung and breast cancer) [4,5].…”

Section: Rhenium (V) Complexesmentioning

confidence: 99%

Rhenium-188 Radiochemistry: Challenges and Prospects

Blower¹

2017

Int. J. Nucl. Medi. Res.

View full text Add to dashboard Cite

After a lull in development of new chemistry for rhenium-188 and technetium-99m since 2000, there has been new investment in production facilities for Mo-99/Tc-99m coupled with increasing interest in rhenium-188 radionuclide therapy, particularly in developing countries. Much of the chemistry developed in the 1990s is not readily amenable to supporting modern radiopharmaceutical development, which places increased emphasis on molecular targeted radiopharmaceuticals. Consequently there is a need for new radiolabelling chemistry to incorporate these radionuclides into biomolecules using simple, kit-based methodology. This review provides an update on progress towards simple rhenium-188 labelling methods since 2000.

show abstract

Development of 4-hexadecyl-4,7-diaza-1,10-decanedithiol (HDD) kit for the preparation of the liver cancer therapeutic agent Re-188-HDD/lipiodol

Cited by 10 publications

References 17 publications

Transarterial Radionuclide Therapy with 188Re-Labelled Lipiodol

Transarterial Radionuclide Therapy with 188Re-Labelled Lipiodol

Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives

Rhenium-188 Radiochemistry: Challenges and Prospects

Contact Info

Product

Resources

About